

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 022128-000300US 10/665,974 09/18/2003 Mark E. Deem 5366 EXAMINER 20350 7590 01/25/2006 TOWNSEND AND TOWNSEND AND CREW, LLP PEFFLEY, MICHAEL F TWO EMBARCADERO CENTER ART UNIT PAPER NUMBER **EIGHTH FLOOR** SAN FRANCISCO, CA 94111-3834 3739

DATE MAILED: 01/25/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		$\epsilon$	
	Application No.	Applicant(s)	
Office Action Summary	10/665,974	DEEM ET AL.	
	Examiner	Art Unit	
	Michael Peffley	3739	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION IN no event, however, may a reply be will apply and will expire SIX (6) MONTHS from cause the application to become ABANDON	ON. timely filed m the mailing date of this communication. IED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 14 November 2005.			
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ This	,—		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is			
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4)⊠ Claim(s) 18-23,54-60 and 76 is/are pending in the application.			
4a) Of the above claim(s) 54,56 and 58-60 is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>18-23, 55, 57 and 76</u> is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/or election requirement.			
Application Papers			
9) The specification is objected to by the Examine	r.		
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:			
1. Certified copies of the priority documents have been received.			
2. Certified copies of the priority documents have been received in Application No			
3. Copies of the certified copies of the priority documents have been received in this National Stage			
application from the International Bureau (PCT Rule 17.2(a)).			
* See the attached detailed Office action for a list of the certified copies not received.			
		•	
Attachment(s)			
1) Notice of References Cited (PTO-892)	4) Interview Summa	ary (PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail	Date	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 13 11 (03	5)	I Patent Application (PTO-152)	
S. Patent and Trademark Office	· — —		

Application/Control Number: 10/665,974

Art Unit: 3739

## Election/Restrictions

Applicant's election without traverse of the invention of Group I, claims 18-23 and 54-60 in the reply filed on November 9, 2005 is acknowledged. Applicant has further elected the embodiment of Figures 5A-5D, claims 18-23, 55, 57 and newly added claim 76. Claims 54, 56 and 58-60 are withdrawn from further consideration.

## Claim Objections

The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claim 75 has been renumbered 76. It is noted that applicant's response indicates that the newly added claims is numbered 76. However, the copy of the claims shows claims 61-75 canceled then newly added claim 75. Again, this claim has been renumbered as claim 76, and applicant should indicate such a change in future responses. *Claim Rejections - 35 USC § 103* 

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

<sup>(</sup>a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 18-23, 55, 57 and 76 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chanduszko et al (2003/0144694) in view of the teaching of Ginn et al (6,391,048).

Chanduszko et al disclose a closure device and method for treating a PFO. In particular, Chanduszko et al advance a closure devices provided at the distal end of a catheter (see Figures 3 and 5) to a PFO and fix the closure device to close the PFO. The closure device comprises a coating which may be bioresorbable or non-resorbable (paragraph 0031). Chanduszko et al fail to specifically disclose applying energy to the closure device for fixing the closure device to tissue of the PFO.

Ginn et al disclose an analogous device for closing and/or sealing openings in vascular tissue. In particular, Ginn et al disclose a catheter device with a closure device at the distal end very much like the Chanduszko et al system. More specifically, Ginn et al teach that the closure device may be inserted to seal tissue (e.g. like the Chanduszko et al system). Ginn et al also teach of the use of a tissue adhesive and/or solder to seal tissue, as well as providing RF energy to the closure device to fix the closure device in place (see col. 5, lines 38-56 and col. 8, lines 20-32 and col. 9, lines 28-40).

To have provided the Chanduszko et al system with a means for providing energy to the closure device to assist in securing the device in tissue would have been an obvious consideration for one of ordinary skill in the art in view of the teaching of Ginn et al.

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

Application/Control Number: 10/665,974

Art Unit: 3739

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 18-23, 55, 57 and 76 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-24 of U.S. Patent No. 6,939,348. Although the conflicting claims are not identical, they are not patentably distinct from each other because the method steps recited in the patented claims and the instant application claims recite only minor, obvious differences.

Claims 18-23, 55, 57 and 76 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over the pending claims of copending Application Nos. 10/787,532; 10/811,228; 10/873,348; and 11/053,274. Although the conflicting claims are not identical, they are not patentably distinct from each other because there are only minor, obvious differences between the instant application claims and the method claims of the other pending applications.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Art Unit: 3739

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Stambaugh et al (5,919,200) discloses a catheter device that applies energy to tissue during treatment of a PFO. Malecki et al (5,626,607) disclose a clamp assembly that may deliver RF energy during treatment of a PFO. Auth et al (2004/0243122) disclose another energy treatment device for the treatment of a PFO, and Opolski (2003/0045901) disclose a catheter system for treatment of a PFO.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Peffley whose telephone number is (571) 272-4770. The examiner can normally be reached on Mon-Fri from 6am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda Dvorak can be reached on (571) 272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael Peffley
Primary Examiner
Art Unit 3789

Mp January 10, 2006